VIP: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โข3 community protocols documented
- โขEvidence level: Structured Community Data
- โขBased on 60 community reports
- โข2 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Protocol Prerequisites | In Dr. Shoemaker's CIRS protocol, VIP is the 11th and final treatment step, used only after completing all prior steps including cholestyramine binding, MARCoNS eradication, and passing VCS testing. | Some community members attempt VIP therapy without completing prerequisite CIRS treatment steps. Others use VIP outside of the CIRS framework entirely for general anti-inflammatory or neuropeptide benefits. | high Using VIP without completing prerequisite steps may reduce efficacy or cause issues. The Shoemaker protocol emphasizes sequential treatment. |
| Indication | Published research on VIP in CIRS focuses on patients meeting strict diagnostic criteria for chronic inflammatory response syndrome following water-damaged building exposure. VIP is also studied for pulmonary arterial hypertension. | Community use extends to general chronic fatigue, brain fog, respiratory conditions, and as a broad anti-inflammatory neuropeptide. Some practitioners use it for conditions beyond the strict CIRS framework. | moderate VIP's broad physiological roles provide theoretical rationale for wider use, but clinical evidence is limited to specific CIRS and PAH contexts. |
| Route of Administration | Research and clinical use primarily employs intranasal VIP spray for CIRS and inhaled VIP for pulmonary conditions. | Community uses nasal spray (most common), subcutaneous injection (occasional), and nebulized forms. The nasal spray route aligns with clinical protocols. | low The community preference for intranasal delivery aligns well with published clinical protocols. |
Compare these community approaches with published research findings.
Community Protocols
CIRS/Mold Illness Nasal Spray Protocol
Popular- Route
- Intranasal
- Dose
- 50 mcg per spray (4-8 sprays daily)
- Frequency
- 4-8 times daily
- Duration
- 30+ days
Final step in Dr. Shoemaker CIRS protocol; requires passing VCS and MARCoNS eradication first
Standard Nasal Spray Protocol
Common- Route
- Intranasal
- Dose
- 50 mcg per spray
- Frequency
- 2 sprays twice daily (escalating)
- Duration
- 8-12 weeks
Weeks 1-2 at 50 mcg twice daily, weeks 3-4 at 100 mcg twice daily, month 2+ at 200 mcg twice daily
Subcutaneous VIP Protocol
Niche- Route
- Subcutaneous
- Dose
- 50-100 mcg
- Frequency
- Once daily
- Duration
- 4-8 weeks
Less common route; some practitioners prefer SubQ for systemic effects beyond nasal/respiratory
Stacking Patterns
CIRS Treatment Stack
CommonVIP for final-stage CIRS treatment combined with BPC-157 for gut healing; addressing both systemic inflammation and intestinal barrier repair
CIRS + Immune Stack
NicheVIP for CIRS symptom management with thymosin alpha-1 for adaptive immune support; used in complex chronic inflammatory conditions
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 60+ self-experimenters report. Free with email.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Sources
- Surviving Mold|VIP corrects chronic inflammatory response syndrome (published study)(accessed 2026-02-16)
- Surviving Mold|Support for Use of VIP in SEID(accessed 2026-02-16)
- Dr. Jill Carnahan|Vasoactive Intestinal Peptide (VIP): Therapeutic Uses(accessed 2026-02-16)
- Biotoxin Journey|Vasoactive Intestinal Peptide (VIP) in CIRS treatment(accessed 2026-02-16)
- Richmond Functional Medicine|Part 4 CIRS Treatment Pathway - VIP protocol(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for VIP (Vasoactive Intestinal Peptide). The information below is gathered from CIRS/mold illness communities, functional medicine practitioners, and patient experience reports. This is not clinical evidence and should not be used as medical guidance.
VIP has an established niche in the functional medicine and mold illness communities as the final treatment step in the Shoemaker CIRS (Chronic Inflammatory Response Syndrome) protocol. It has been reported to be used in over 10,000 patients within this framework, giving it one of the larger community evidence bases among immune-related peptides.
Understanding Protocol Divergence#
Sequential Treatment Context#
The most important aspect of VIP community use is its position as the final step in a multi-stage treatment protocol. The Shoemaker CIRS protocol involves 11 sequential steps, with VIP as the last. This means VIP is not used as a standalone treatment but as the culmination of a comprehensive approach that includes biotoxin binding (cholestyramine), MARCoNS eradication, and environmental remediation.
Prerequisite Requirements#
Community protocols emphasize strict prerequisites before initiating VIP, including passing VCS testing, completing ERMI mold testing, eradicating MARCoNS, and normalizing fasting lipase. Some community members attempt to bypass these prerequisites, which practitioners caution may reduce efficacy or cause issues.
Commonly Reported Outcomes#
Community members and patients following the CIRS protocol report:
- Cognitive improvement: Reduced brain fog and improved mental clarity
- Energy restoration: Significant improvement in chronic fatigue
- Respiratory improvement: Better breathing and reduced respiratory symptoms
- Hormonal normalization: Some users report improvement in dysregulated hormone markers
Important Caveats#
- VIP is most effective as part of the complete CIRS protocol, not as a standalone treatment
- Skipping prerequisite treatment steps may reduce efficacy
- The Shoemaker CIRS protocol is not universally accepted in conventional medicine
- VIP nasal spray requires compounding pharmacy prescription
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About VIP
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.